Healthcare ❯ Pharmaceuticals

Biotechnology

Drug Development Clinical Trials Immunology Oncology Investment Opportunities Gene Therapy Investment Strategies Market Trends Rare Diseases Healthcare Companies Inflammatory Diseases Mental Health Multiple Sclerosis Treatments Industry Analysis Obesity Treatments Biopharmaceuticals Vaccines Combination Treatments Company Performance Immunotherapy Genomics Antibody Therapies Research and Development Vaccine Development Cardiovascular Treatments Product Sales Drug Discovery Diabetes Treatments Stock Performance Commercial-stage Biotech Acquisitions Cancer Treatment Corporate Strategies Regeneron Moderna Immunoglobulin Dividend Stocks Company News Corporate Events Product Launch Company Announcements UroGen Pharma Publicly Traded Companies Medical Equipment Digital Health Corporate Healthcare Regeneron Pharmaceuticals Therapeutic Areas Corporate Finance Clinical Development Gene Editing Medical Innovation Regulatory Compliance Healthcare Investments CAR-T Therapy Product Development Cell Therapy

Xenon Files FDA New Drug Application for Azetukalner After Pause in Depression Trials

The submission advances a potential first epilepsy approval while unresolved neuropsychiatric signals could force dosing changes or further study.

Pharma Dividend Trade-Off: Pfizer's High Yield Versus AbbVie's Durability and Lilly's Growth

Amgen's Cash Strength Versus Moderna's mRNA Pivot

Capricor Faces Securities Class Action as FDA Extends Review of Duchenne Therapy

Lilly to Buy Merida Biosciences for Up to $2.875 Billion

Legend Biotech Posts First Profitable Quarter as CARVYKTI Sales Reach $657 Million

SPGM Positions as a Low‑Cost All‑Cap Global Core but Keeps Heavy U.S. Tech Overlap

Dassault Systèmes Agrees to Buy ArisGlobal From Nordic Capital

Picking Between Broad Healthcare ETFs and Biotech-Focused Plays

Equal Costs, Unequal Risk: BBH’s Concentration Versus XPH’s Breadth

Healthcare ETFs Force a Choice Between Low Cost and Higher Growth

Pfizer Posts Higher Q1 Sales but Lower Profit, Raising Fresh Questions About Its Dividend

Rhythm Pharmaceuticals Jumps on Q1 Beat Driven by Imcivree

Baron Health Care Fund Falls 6.97% in Q1, Repositions for Long-Term Growth

Moderna Beats Q1 Forecast as Overseas COVID Shot Sales Rebound

AbbVie Tops Q1 and Raises 2026 Outlook as Skyrizi and Rinvoq Offset Humira Decline

Cyclerion to Merge With Korsana in Reverse Takeover Backed by $380 Million

Krystal Biotech Posts Strong Q4 as VYJUVEK Hits $107 Million, Pivots 2026 Growth to Ex‑U.S. Markets

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Eli Lilly’s Q4 Beat and Bullish Outlook Give Way to Stock Drop on Low-Cost GLP-1 Pills